PAHC icon

Phibro Animal Health

32.72 USD
+0.78
2.44%
Updated Aug 26, 1:00 PM EDT
1 day
2.44%
5 days
3.54%
1 month
13.14%
3 months
33.77%
6 months
47.06%
Year to date
57.84%
1 year
54.78%
5 years
60.87%
10 years
-4.69%
 

About: Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.

Employees: 1,940

0
Funds holding %
of 7,431 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

41% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 22

19% more capital invested

Capital invested by funds: $434M [Q1] → $518M (+$83.7M) [Q2]

3% more funds holding

Funds holding: 184 [Q1] → 189 (+5) [Q2]

4% more repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 67

0.11% less ownership

Funds ownership: 99.62% [Q1] → 99.51% (-0.11%) [Q2]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$26
21%
downside
Avg. target
$31
7%
downside
High target
$35
7%
upside

2 analyst ratings

positive
50%
neutral
50%
negative
0%
JP Morgan
Ekaterina Knyazkova
7%upside
$35
Overweight
Upgraded
7 Jul 2025
Morgan Stanley
Erin Wright
21%downside
$26
Equal-Weight
Maintained
25 Jun 2025

Financial journalist opinion

Based on 11 articles about PAHC published over the past 30 days

Neutral
Zacks Investment Research
4 days ago
Insights Into Phibro (PAHC) Q4: Wall Street Projections for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Phibro (PAHC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
Insights Into Phibro (PAHC) Q4: Wall Street Projections for Key Metrics
Neutral
Business Wire
5 days ago
Phibro Animal Health Corporation to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2025 Results
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its fourth quarter and fiscal year 2025 financial results on Wednesday, August 27, 2025, after the market closes. Phibro management will host a conference call and webcast on Thursday, August 28, 2025, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be availab.
Phibro Animal Health Corporation to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2025 Results
Positive
Zacks Investment Research
6 days ago
PAHC vs. BSX: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Products stocks have likely encountered both Phibro Animal Health (PAHC) and Boston Scientific (BSX). But which of these two stocks is more attractive to value investors?
PAHC vs. BSX: Which Stock Is the Better Value Option?
Neutral
Zacks Investment Research
6 days ago
Should Value Investors Buy Phibro Animal Health (PAHC) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy Phibro Animal Health (PAHC) Stock?
Positive
Zacks Investment Research
6 days ago
Phibro Animal Health Corporation (PAHC) Hits Fresh High: Is There Still Room to Run?
Phibro (PAHC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Phibro Animal Health Corporation (PAHC) Hits Fresh High: Is There Still Room to Run?
Positive
Zacks Investment Research
6 days ago
PAHC Stock Up 76.4% in a Year: What's Driving the Rally?
Phibro Animal Health's 76.4% stock surge is fueled by strong sales recovery, global growth and a robust balance sheet.
PAHC Stock Up 76.4% in a Year: What's Driving the Rally?
Positive
Zacks Investment Research
1 week ago
Phibro (PAHC) is an Incredible Growth Stock: 3 Reasons Why
Phibro (PAHC) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Phibro (PAHC) is an Incredible Growth Stock: 3 Reasons Why
Positive
Zacks Investment Research
3 weeks ago
PAHC vs. LMAT: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Products stocks have likely encountered both Phibro Animal Health (PAHC) and LeMaitre Vascular (LMAT). But which of these two stocks presents investors with the better value opportunity right now?
PAHC vs. LMAT: Which Stock Should Value Investors Buy Now?
Positive
Zacks Investment Research
3 weeks ago
Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?
Positive
Zacks Investment Research
3 weeks ago
3 Reasons Growth Investors Will Love Phibro (PAHC)
Phibro (PAHC) possesses solid growth attributes, which could help it handily outperform the market.
3 Reasons Growth Investors Will Love Phibro (PAHC)
Charts implemented using Lightweight Charts™